DPI-3290 is a specific agonist of opioid receptors (Ki: 0.18 nM, 0.46 nM, and 0.62 nM for δ-, μ-, and κ-opioid receptors, respectively) with potent antinociceptive activity. DPI-3290 is one of a series of novel centrally acting agents.
Carmegliptin dihydrochloride is the salt form of Camegliptin (free base), also known as RG-1579 and RO4876904, a dipeptidyl peptidase IV (DPP-4) inhibitor potentially for the treatment of type 2 diabetes.